News

The menopause market is projected to increase at a CAGR of 5.10% between 2025 – 2033, with North America making up 4.9% during this period.

Marty Makary, M.D., M.P.H., as FDA administrator may be the least controversial of Trump's picks for the top healthcare jobs so far.

Here’s what you missed this week on Managed Healthcare Executive.

Patient follow-up 10 years after hormone replacement therapy treatment revealed there were no long-term negative cognitive effects.

In a recent conversation with Greg Baker, CEO of AffirmedRx, the PBM professional outlined the company’s distinct approach in the PBM industry with MHE editors.

Gene therapies have a lot of potential to improve health outcomes for patients with life-threatening diseases but face a number of barriers that restrict access.

Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.

Kennedy's vaccines may give some Republican senators pause while Oz has an ally in Medicare Advantage plans.

The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.

Medicare fraud costs Americans about $60 billion each year and healthcare plans are stepping in spread awareness and stop criminals.

Mehmet Oz, M.D., is another unconventional pick by Trump and is perhaps another an indication that Trump intends to let his HHS secretary nominee, Robert F. Kennedy Jr., "go wild on health."

Relapsed or refractory acute leukemia with a KMT2A translocation currently has an overall survival rate of less than one year when treated with frontline therapies.

Researchers are currently enrolling participants to test the effectiveness of a rectal douche containing the antiretroviral drug tenofovir in a study that is expected to finish in January 2026.

Breast cancer treatment settings prove to be a good opportunity to talk about financial toxicity. These conversations can also happen in generalized healthcare, according to Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.

In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.

Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.

Here’s what you missed this week on Managed Healthcare Executive.

Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University explains the concept of financial toxicity and how it affects breast cancer treatment outcomes.

Canadian study reveals that women who undergo early menopause are less at risk for asthma than women who experience menopause late.

Member experience, outcomes and medication adherence are the key areas of performance that Medicare Advantage plans should focus on to improve Star Ratings.

A new study found that iron supplements are safe for children with HIV in Uganda, as they improve hemoglobin levels without increasing malaria risk.

A recent study reveals that nearly 20% of United States physicians treating HIV patients plan to leave or reduce their caseload within five years, even as demand for HIV care is expected to rise.

In a response to a survey, caregivers of people with spinal muscular atrophy identified the risk of severe adverse events and the need for permanent ventilation as the most important factors in treatment decisions. Access to treatment, including cost and availability, ranked third.

Mouse models of liver, kidney and lung fibrosis showed that genetic deletion of MERTK prevented fibrosis

If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date is August 21, 2025.

Here’s what you missed this week on Managed Healthcare Executive.

Type 1 diabetes is a relentless disease, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.